TY  - JOUR
AU  - Liabeuf, Sophie
AU  - Pešić, Vesna
AU  - Spasovski, Goce
AU  - Maciulaitis, Romaldas
AU  - Bobot, Mickaël
AU  - Farinha, Ana
AU  - Wagner, Carsten A.
AU  - Unwin, Robert J.
AU  - Capasso, Giovambattista
AU  - Bumblyte, Inga Arune
AU  - Hafez, Gaye
PY  - 2023
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/5225
AB  - People living with chronic kidney disease (CKD) frequently suffer from mild cognitive impairment and/or other
neurocognitive disorders. This review in two parts will focus on adverse drug reactions resulting in cognitive impairment
as a potentially modifiable risk factor in CKD patients. Many patients with CKD have a substantial burden of
comorbidities leading to polypharmacy. A recent study found that patients seen by nephrologists were the most complex
to treat because of their high number of comorbidities and medications. Due to polypharmacy, these patients may
experience a wide range of adverse drug reactions. Along with CKD progression, the accumulation of uremic toxins may
lead to blood–brain barrier (BBB) disruption and pharmacokinetic alterations, increasing the risk of adverse reactions
affecting the central nervous system (CNS). In patients on dialysis, the excretion of drugs that depend on kidney
function is severely reduced such that adverse and toxic levels of a drug or its metabolites may be reached at relatively
low doses, unless dosing is adjusted. This first review will discuss how CKD represents a risk factor for adverse drug
reactions affecting the CNS via (i) BBB disruption associated with CKD and (ii) the impact of reduced kidney function and
dialysis itself on drug pharmacokinetics.
PB  - Oxford University Press ( Oxford Academic)
T2  - Clinical Kidney Journal
T1  - Drugs with a negative impact on cognitive function (Part 1): chronic kidney disease as a risk factor
VL  - 0
IS  - 0
SP  - 1
EP  - 13
DO  - 10.1093/ckj/sfad241
ER  - 

@article{
author = "Liabeuf, Sophie and Pešić, Vesna and Spasovski, Goce and Maciulaitis, Romaldas and Bobot, Mickaël and Farinha, Ana and Wagner, Carsten A. and Unwin, Robert J. and Capasso, Giovambattista and Bumblyte, Inga Arune and Hafez, Gaye",
year = "2023",
abstract = "People living with chronic kidney disease (CKD) frequently suffer from mild cognitive impairment and/or other
neurocognitive disorders. This review in two parts will focus on adverse drug reactions resulting in cognitive impairment
as a potentially modifiable risk factor in CKD patients. Many patients with CKD have a substantial burden of
comorbidities leading to polypharmacy. A recent study found that patients seen by nephrologists were the most complex
to treat because of their high number of comorbidities and medications. Due to polypharmacy, these patients may
experience a wide range of adverse drug reactions. Along with CKD progression, the accumulation of uremic toxins may
lead to blood–brain barrier (BBB) disruption and pharmacokinetic alterations, increasing the risk of adverse reactions
affecting the central nervous system (CNS). In patients on dialysis, the excretion of drugs that depend on kidney
function is severely reduced such that adverse and toxic levels of a drug or its metabolites may be reached at relatively
low doses, unless dosing is adjusted. This first review will discuss how CKD represents a risk factor for adverse drug
reactions affecting the CNS via (i) BBB disruption associated with CKD and (ii) the impact of reduced kidney function and
dialysis itself on drug pharmacokinetics.",
publisher = "Oxford University Press ( Oxford Academic)",
journal = "Clinical Kidney Journal",
title = "Drugs with a negative impact on cognitive function (Part 1): chronic kidney disease as a risk factor",
volume = "0",
number = "0",
pages = "1-13",
doi = "10.1093/ckj/sfad241"
}

Liabeuf, S., Pešić, V., Spasovski, G., Maciulaitis, R., Bobot, M., Farinha, A., Wagner, C. A., Unwin, R. J., Capasso, G., Bumblyte, I. A.,& Hafez, G.. (2023). Drugs with a negative impact on cognitive function (Part 1): chronic kidney disease as a risk factor. in Clinical Kidney Journal
Oxford University Press ( Oxford Academic)., 0(0), 1-13.
https://doi.org/10.1093/ckj/sfad241

Liabeuf S, Pešić V, Spasovski G, Maciulaitis R, Bobot M, Farinha A, Wagner CA, Unwin RJ, Capasso G, Bumblyte IA, Hafez G. Drugs with a negative impact on cognitive function (Part 1): chronic kidney disease as a risk factor. in Clinical Kidney Journal. 2023;0(0):1-13.
doi:10.1093/ckj/sfad241 .

Liabeuf, Sophie, Pešić, Vesna, Spasovski, Goce, Maciulaitis, Romaldas, Bobot, Mickaël, Farinha, Ana, Wagner, Carsten A., Unwin, Robert J., Capasso, Giovambattista, Bumblyte, Inga Arune, Hafez, Gaye, "Drugs with a negative impact on cognitive function (Part 1): chronic kidney disease as a risk factor" in Clinical Kidney Journal, 0, no. 0 (2023):1-13,
https://doi.org/10.1093/ckj/sfad241 . .

TY  - JOUR
AU  - Liabeuf, Sophie
AU  - Pepin, , Marion
AU  - Franssen, Casper F.M.
AU  - Viggiano, Davide
AU  - Carriazo, Sol
AU  - Gansevoort, Ron T.
AU  - Gesualdo, Loreto
AU  - Hafez, Gaye
AU  - Malyszko, Jolanta
AU  - Mayer, Christopher
AU  - Nitsch, Dorothea
AU  - Ortiz, Alberto
AU  - Pešić, Vesna
AU  - Wiecek, Andrzej
AU  - Massy, Ziad
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4029
AB  - Chronic kidney disease (CKD) perturbs the crosstalk with others organs, with the interaction between the kidneys and the heart having been studied most intensively. However, a growing body of data indicates that there is an association between kidney dysfunction and disorders of the central nervous system. In epidemiological studies, CKD is associated with a high prevalence of neurological complications, such as cerebrovascular disorders, movement disorders, cognitive impairment and depression. Along with traditional cardiovascular risk factors (such as diabetes, inflammation, hypertension and dyslipidaemia), non-traditional risk factors related to kidney damage (such as uraemic toxins) may predispose patients with CKD to neurological disorders. There is increasing evidence to show that uraemic toxins, for example indoxyl sulphate, have a neurotoxic effect. A better understanding of factors responsible for the elevated prevalence of neurological disorders among patients with CKD might facilitate the development of novel treatments. Here, we review (i) the potential clinical impact of CKD on cerebrovascular and neurological complications, (ii) the mechanisms underlying the uraemic toxins' putative action (based on pre-clinical and clinical research) and (iii) the potential impact of these findings on patient care.
PB  - Oxford University Press
T2  - Nephrology Dialysis Transplantation
T1  - Chronic kidney disease and neurological disorders: are uraemic toxins the missing piece of the puzzle?
VL  - 37
IS  - supplement 2
SP  - ii33
EP  - ii44
DO  - 10.1093/ndt/gfab223
ER  - 

@article{
author = "Liabeuf, Sophie and Pepin, , Marion and Franssen, Casper F.M. and Viggiano, Davide and Carriazo, Sol and Gansevoort, Ron T. and Gesualdo, Loreto and Hafez, Gaye and Malyszko, Jolanta and Mayer, Christopher and Nitsch, Dorothea and Ortiz, Alberto and Pešić, Vesna and Wiecek, Andrzej and Massy, Ziad",
year = "2022",
abstract = "Chronic kidney disease (CKD) perturbs the crosstalk with others organs, with the interaction between the kidneys and the heart having been studied most intensively. However, a growing body of data indicates that there is an association between kidney dysfunction and disorders of the central nervous system. In epidemiological studies, CKD is associated with a high prevalence of neurological complications, such as cerebrovascular disorders, movement disorders, cognitive impairment and depression. Along with traditional cardiovascular risk factors (such as diabetes, inflammation, hypertension and dyslipidaemia), non-traditional risk factors related to kidney damage (such as uraemic toxins) may predispose patients with CKD to neurological disorders. There is increasing evidence to show that uraemic toxins, for example indoxyl sulphate, have a neurotoxic effect. A better understanding of factors responsible for the elevated prevalence of neurological disorders among patients with CKD might facilitate the development of novel treatments. Here, we review (i) the potential clinical impact of CKD on cerebrovascular and neurological complications, (ii) the mechanisms underlying the uraemic toxins' putative action (based on pre-clinical and clinical research) and (iii) the potential impact of these findings on patient care.",
publisher = "Oxford University Press",
journal = "Nephrology Dialysis Transplantation",
title = "Chronic kidney disease and neurological disorders: are uraemic toxins the missing piece of the puzzle?",
volume = "37",
number = "supplement 2",
pages = "ii33-ii44",
doi = "10.1093/ndt/gfab223"
}

Liabeuf, S., Pepin, ,. M., Franssen, C. F.M., Viggiano, D., Carriazo, S., Gansevoort, R. T., Gesualdo, L., Hafez, G., Malyszko, J., Mayer, C., Nitsch, D., Ortiz, A., Pešić, V., Wiecek, A.,& Massy, Z.. (2022). Chronic kidney disease and neurological disorders: are uraemic toxins the missing piece of the puzzle?. in Nephrology Dialysis Transplantation
Oxford University Press., 37(supplement 2), ii33-ii44.
https://doi.org/10.1093/ndt/gfab223

Liabeuf S, Pepin ,M, Franssen CF, Viggiano D, Carriazo S, Gansevoort RT, Gesualdo L, Hafez G, Malyszko J, Mayer C, Nitsch D, Ortiz A, Pešić V, Wiecek A, Massy Z. Chronic kidney disease and neurological disorders: are uraemic toxins the missing piece of the puzzle?. in Nephrology Dialysis Transplantation. 2022;37(supplement 2):ii33-ii44.
doi:10.1093/ndt/gfab223 .

Liabeuf, Sophie, Pepin, , Marion, Franssen, Casper F.M., Viggiano, Davide, Carriazo, Sol, Gansevoort, Ron T., Gesualdo, Loreto, Hafez, Gaye, Malyszko, Jolanta, Mayer, Christopher, Nitsch, Dorothea, Ortiz, Alberto, Pešić, Vesna, Wiecek, Andrzej, Massy, Ziad, "Chronic kidney disease and neurological disorders: are uraemic toxins the missing piece of the puzzle?" in Nephrology Dialysis Transplantation, 37, no. supplement 2 (2022):ii33-ii44,
https://doi.org/10.1093/ndt/gfab223 . .